Antidepressive efficacy of quetiapine XR in unipolar major depression - The role of early onset of action and sleep-improving effect in decreasing suicide risk;A quetiapin XR antidepresszív hatása unipoláris major depresszióban: A korai hatáskezdet és az alvásjavító hatás szerepe az öngyilkossá gi kockázat csökkentésében

Neuropsychopharmacologia Hungarica

Volumn 11, Issue 4, 2009, Pages 211-215

  Zoltán, Rihmer ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Insomnia; Major depression; Mirtazapine; Side effects; Suicide

Indexed keywords

QUETIAPINE;

AGITATION; ANXIETY DISORDER; DRUG EFFICACY; HUMAN; INSOMNIA; MAJOR DEPRESSION; REVIEW; RISK REDUCTION; SLEEP INDUCTION; SUICIDAL BEHAVIOR;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; HUMANS; SLEEP; SUICIDE; TREATMENT OUTCOME;

EID: 77749327467     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Agargun MY, Besiroglu L, Cilli AS, et al, (2007). Nightmares, suicide attempts, and melancholic features in patients with unipolar major depression. J Affect Disord, 98: 267-270.
2. Almási J, Rihmer Z. (2004). Az antidepresszívumok áttekintése a TCA-któl a harmadik generációs szerekig. Neuropsychopharmacol Hung, 6: 185-194.
3. Altamura AC, Dell'Osso B, Vismara S, Mundo E. (2008a). May duration of untreated illness influence the long-term cousre of major depressive disorder? Eur Psychiatry, 23: 92-96.
4. Altamura AC, Mundo E, Dell'Osso B. et a. (2008b). Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: A 4-year floow-up naturalistic study. J Affect Disord, 110: 135-141.
5. Benkert O, Szegedi A, Kohnen R.(2000). Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry, 61: 656-663.
6. Bowden CL, Grunze H, Mullen J. et al. (2005). A randomized, double-blind, placebo controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry, 66: 111-121.
7. Calabrese JR, Keck PE, Macfadden W. et al, (2005). A randomized, double-blind, placebo controlled trial of quetiapine in the treatment of bipolar I or Ii depression. Am J Psychiatry, 162: 1351-1360.
8. Cutler AJ, Montgomery SA, Feifel D. et al, (2009). Extended release quetiapine fumarat monotherapy in major depressive disorder: A placebo- and duloxetine-controlle study. J Clin Psychiatry, 70: 526-539.
9. Dannlowski U, Baune BT, Böckermann I. et al. (2009). Adjunctive antidepressant treatment with quetiapine in agitated depression: Posotove effects on symptom reduction, psychopathology and remission rates. Human Psychopharmacol, DOI: 10.1002/hup-963
10. Dorée J-P, Rosiers JD, Lew V. et a. (2007). Quetiapine augmentation of treatent-resistant depression: A comparison with lithium. Curr Med Res Op, 23: 333-341.
11. Fawcet J, Scheftner WA, Fogg L. és mtsai (1990). Time-related predictors of suicide in major affetctive disorder. Am J Psychiatry 147: 1189-1194.
12. Fountoulakis KN, Vieta E. (2008). Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol, 11: 999-1029.
13. Gartlehner G, Morgan LC, Thieda P és mtsai (2008a). Drug Class Review Second Generation Antidepressants Final Report Update 4. OHSU Drug Effectiveness Research Project www.ohsu.edu/ohsuedu/research/policycenter/ customcf/derp/product/AD2-final-report-update%2041.pdf
14. Gartlehner G, Gaynes BN, Hansen RA. és mtsai (2008b). Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 149: 734-50
15. Goodwin FK. és Jamison KR. (2007). Manic-Depressive Illness. Bipolar Disorders and Recurrent Depression. 2nd edition. Oxford University Press, New York.
16. Henkel V, Seemüller F, Obermeier M. et al, (2009). Doeas early improvmenet triggered by antidepressants predict response/remission? - Analyis of data from a naturalsitic study on a large sample of inaptients with major depression. J Affect Disord, 115: 439-449.
17. Jefferson JW. (2008). Strategies for switching antidepressants to achieve maximum efficacy. J Clin Psychiatry, 69 (Suppl. E1): 14-18.
18. Jick H, Kaye JA, Jick SS: Antidepressants and the risk of suicidal behavior. JAMA, 2004; 292: 338-348.
19. Kasper S, Spadone C, Verpillat P, et al. (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol, 21: 105-110.
20. Kent JM. (2000). SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet, 355: 911-918.
21. Kornstein SG. és Schneider RK. (2001). Clinical features of treatment-resistant depression. J Clin Psychiatry, 62 (suppl.16): 18-25.
22. Liebowitz MR, Salmán E, Mech A, et al. (2009). Ziprasidone monotherapy in bipolar II depression: An open trial. J Affect Disord, 118: 205-208.
23. McGirr A, Renaud J, Seguin M, et al. (2007). An examination of DSM-IV depressive symptoms and risk of suicide completion in major depressive disorder. A psychological autopsy study. J Affect Disord, 97: 203-209.
24. Paffenbarger RS, Lee IM, Leung R. (1994). Physical activity and personal characteristics associated with depression and suicide in American college men. Acta Psychiat Scand 337S: 16-22.
25. Papakostas GI, Fava M, Thase ME. (2008). Treatment of SSRI-resistant depression: A meta-analysis comparing within-versus accross-class switches. Biol. Psychiatry, 63: 699-704.
26. Rihmer Z, Aksikal HS. (2006). Do antidepressants t(h)reat(en) depressives? Toward a judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide rates from many countries. J Affect Disord, 94: 3-13.
27. Rihmer Z. (2007). Suicide rsik in mood disorders. Curr Opin Psychiat, 20: 17-22.
28. Rihmer Z. (2008) A bipoláris betegség korszerucombining double acute accent nozológiája. Neuropsychopharmacol Hung, 10: (Suppl. 3), 5-12.
29. Sagud M, Mihaljevic-Peles A, Mück-Seler D. et al. (2006). Quetiapine augmentation in treatment-resistant depression: A naturalistic study. Psychopharmacology, 187: 511-514.
30. San L, Arranz B. (2008). Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry, 23: 396-402.
31. Simon GE, Savarino J, Operskalski B, Wang PS.: Suicide risk during antidepressant treatment. Amer J Psychiatry, 2006; 163: 41-47.
32. Tandon R. (2004). Quetiapine has a direct effect on the negative syptoms of schizophrenia. Human Psychopharmacol, 19: 559-563.
33. Taylor DJ. Lichstein KL. Durrence HH. (2003). Insomnia as a health risk factor. Behav Sleep Med 1: 227-47.
34. Thase ME, Macfadden W, Weisler RH. Et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and Ii depression. J Clin Psychopharmacol, 26: 600-609.
35. Tohen M., Vieta E., Calabrese J. et al, (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiat. 60, 1079-1088.
36. Tohen M, Calabrese JR, Sachs GS. et al, (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry, 163: 247-256.
37. Tondo L, Lepri B, Baldessarini RJ. (2008). Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiat Scand, 118. 106-115.
38. Zisok S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW, Moutier C, Fava M, Wisniewski SR, Luther J, Rush JA. (2009). Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram int he STAR*D study. J Affect Disord, 117: 63-73.